Results 221 to 230 of about 33,511 (273)

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, Volume 13, Issue 5, Page 1028-1040, May 2026.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin   +11 more
wiley   +1 more source

Traumatic Microhemorrhages Are Not Synonymous With Axonal Injury

open access: yesAnnals of Clinical and Translational Neurology, Volume 13, Issue 5, Page 1060-1065, May 2026.
ABSTRACT Diffuse axonal injury (DAI) is caused by acceleration‐deceleration forces during trauma that shear white matter tracts. Susceptibility‐weighted MRI (SWI) identifies microbleeds that are considered the radiologic hallmark of DAI and are used in clinical prognostication.
Karinn Sytsma   +9 more
wiley   +1 more source

Orientation Engineering of MXene Flakes

open access: yesAdvanced Materials, Volume 38, Issue 25, 4 May 2026.
Orientation engineering of MXene flakes refers to the transformation of disordered MXene flakes into ordered architectures with optimized multiphysical transport properties. Focusing on this topic, this review outlines key principles, characterization, fabrication strategies, and advanced applications of oriented MXene structures.
Yizhou Wang   +7 more
wiley   +1 more source

Cuproptosis and Disulfidptosis Converge to Empower PD‐L1 Checkpoint Therapy via Cadict‐Induced PD‐L1 Translation

open access: yesAdvanced Science, Volume 13, Issue 25, 4 May 2026.
This study introduces Cadict, an EGFR‐targeted nanodrug that co‐delivers cuproptosis and disulfidptosis inducers to overcome immune resistance. Cadict synergistically enhances tumor cytotoxicity and sensitizes cancers to ICIs by upregulating PD‐L1 via an Eif5b‐dependent translation mechanism, fostering a potent antitumor immune response and ...
Shaoqing Huang   +12 more
wiley   +1 more source

GPND‐AI NULISA: A 15‐Protein AI classifier for diagnosis and co‐pathology profiling across neurodegenerative diseases

open access: yesAlzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract INTRODUCTION Accurate clinical diagnosis of neurodegenerative diseases remains challenging, particularly when individuals have mixed pathologies. We implemented the generalizable protein‐based neurodegenerative disease artificial intelligence (GPND‐AI) classifier using the NUcleic acid‐Linked Immuno‐Sandwich Assay (NULISA) central nervous ...
Ying Xu   +25 more
wiley   +1 more source

Usage and positivity rates of Alzheimer's disease biomarkers in a memory clinic

open access: yesAlzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract INTRODUCTION Usage of biomarker tests for Alzheimer's disease pathology and rates of positivity were assessed at the Washington University Memory Diagnostic Center. METHODS Patients who underwent at least one biomarker test for clinical purposes between June 2021 and March 2025 were included (n = 1136). Data were retrospectively extracted from
Anna Hofmann   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy